<DOC>
	<DOCNO>NCT00098982</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Bortezomib may stop growth tumor cell block enzymes need cell growth . It may also help chemotherapy drug work well make tumor cell sensitive drug . Giving bortezomib fluorouracil , leucovorin , oxaliplatin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose bortezomib give fluorouracil , leucovorin , oxaliplatin treat patient advanced metastatic colorectal cancer .</brief_summary>
	<brief_title>Bortezomib , Fluorouracil , Leucovorin , Oxaliplatin Treating Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose bortezomib administer fluorouracil , leucovorin calcium , oxaliplatin patient advance metastatic colorectal cancer . - Determine recommend phase II dose bortezomib patient treat regimen . Secondary - Determine response patient measurable disease treat regimen . OUTLINE : This open-label , non-randomized , multicenter , dose-escalation study bortezomib . Patients receive bortezomib IV 3-5 second day 1 , 8 , 15 ; oxaliplatin IV 2 hour day 1 15 ; leucovorin calcium IV 2 hour fluorouracil IV 22 hour day 1 , 2 , 15 , 16 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Additional patient receive treatment MTD maximum 12 patient dose level . Patients follow every 8 week disease progression start new anticancer treatment . PROJECTED ACCRUAL : Not specify .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic colorectal cancer Amenable firstline treatment oxaliplatin , fluorouracil , leucovorin calcium advance metastatic disease No symptomatic radiologic evidence brain metastasis PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) AST ALT ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine ≤ 1.7 mg/dL Cardiovascular No ischemic heart disease within past 6 month No clinically significant ECG change Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No baseline neuropathy &gt; grade 1 No prior concurrent malignancy except conebiopsied carcinoma cervix adequately treat basal cell squamous cell skin cancer No unstable systemic disease No active uncontrolled infection No psychological , familial , sociological , geographical condition would preclude study participation No hypersensitivity bortezomib , boron , mannitol PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior oxaliplatin No prior chemotherapy advance metastatic disease At least 6 month since prior adjuvant chemotherapy Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy Surgery More 14 day since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>